Feldan Therapeutics

Feldan Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutic products. The company's proprietary technology, the Feldan Shuttle, is a peptide-based delivery platform that enables the safe and efficient cytoplasmic delivery of various bioactive molecules, including proteins, antibodies, and antisense oligonucleotides (ASOs), without the limitations of endosomal entrapment. Feldan's pipeline is focused on addressing diseases affecting the skin and lungs. By enabling access to intracellular targets that were previously inaccessible to conventional drugs, the company aims to develop a new generation of therapies for conditions such as basal cell carcinoma and other localized diseases.